Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL Patients
NCT ID: NCT05577364
Last Updated: 2023-12-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1/PHASE2
54 participants
INTERVENTIONAL
2022-11-01
2026-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Phase Ib study:
Selinexor will be given orally at two different doses (40mg qw, and 60mg qw ) and combined with the R-CHOP regimen from the second cycle based on the "3+3" principle.
In the induction therapy period, 6 cycles of R-CHOP regimen and 2 cycles of rituximab in combination with selinexor are planned.
The dose limited toxicity (DLT) will be evaluated after the first cycle of selinexor in combination with R-CHOP.
Phase II study:
The phase II study of selinexor at recommended phase II dose (RP2D) dose level combined with R-CHOP regimen was conducted to explore the efficacy and safety of the combined regimen.
After 8 cycles of induction therapy, if the response is assessed as complete remission (CR), maintenance therapy with selinexor will be conducted.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Selinexor in Combination With R-CHOP
Patients with untreated EBV-positive diffuse large B-cell lymphoma will receive sequentially higher doses of selinexor in combination with R-CHOP regimen from the second cycle of R-CHOP (3 weeks per cycle).The initial dose of selinexor is 40mg qw po.
After 8 cycles of induction therapy, if the response is assessed as complete remission (CR), maintenance therapy with selinexor will be conducted.
Selinexor
Selinexor: 40mg qw po, and 60mg qw po (phase Ib); RP2D (II study);
Selinexor is added from the second cycle of R-CHOP regimen.
R-CHOP Protocol
Rituximab: 375mg/m2 iv.drip D1;
Cyclophosphamide: 750mg/m2 iv.drip D1;
Doxorubicin: 50mg/m2 iv.drip D1;
Vincristine: 1.4g/m2 iv D1;
Prednisone: 100mg po D1-5;
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Selinexor
Selinexor: 40mg qw po, and 60mg qw po (phase Ib); RP2D (II study);
Selinexor is added from the second cycle of R-CHOP regimen.
R-CHOP Protocol
Rituximab: 375mg/m2 iv.drip D1;
Cyclophosphamide: 750mg/m2 iv.drip D1;
Doxorubicin: 50mg/m2 iv.drip D1;
Vincristine: 1.4g/m2 iv D1;
Prednisone: 100mg po D1-5;
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Age ≥18, ≤70 years, no gender limitation.
3. Histologically confirmed diagnosis of EBV-positive diffuse large B-cell lymphoma (DLBCL) (more than 50% of tumor cells are positive with EBV encoded small RNAs (EBERs) in situ hybridization were considered EBERs positive).
4. Untreated patients, except for the short-time use of prednisone for controlling tumor-induced symptoms (no more than 30mg/d (or other equivalent amounts of other glucocorticoids), no more than 7 days).
5. There must be at least one measurable or evaluable lesion that meets the evaluation criteria for Lugano 2014 lymphoma: measurable lesion: Positron emission tomography/computed tomography (PET/CT) or CT and/or MRI, intranodal lesions with long diameter \>1.5cm, and short diameter \>1.0cm, or extranodal lesions with long diameter \> 1.0 cm.
6. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-2.
7. Expected survival ≥ 3 months.
8. Adequate function of bone marrow:
White blood cell ≥3.0×10E9/L, absolute neutrophil count ≥1.5×10E9/L Platelet ≥100×10E9/L (Bone marrow invasive patient≥75×109/L) Hemoglobin≥ 90g/L No granulocyte growth factor, platelet, or red blood cell transfusions were received within 14 days prior to examination.
9. Adequate function of the liver and renal:
Total bilirubin≤2×upper limit of normal (ULN) (patients with liver invasion or Gilbert syndrome ≤5×ULN) Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN (patients with liver invasion ≤5×ULN) Serum creatinine ≤1.5×ULN or creatinine clearance rate ≥60 mL/min
10. The patients agree to take effective contraceptive measures during the study period and till 12 months after the last administration of the study treatment.
Exclusion Criteria
2. EBV-positive DLBCL with central nervous system invasion.
3. The patients had previously received XPO1 inhibitors, such as selinexor and so on.
4. The patients have contraindications to any drug in the combined treatment.
5. The major surgery is performed within 4 weeks before enrollment, except for diagnosis.
6. There are any life-threatening diseases, medical conditions or organ system dysfunction that the investigator believes may affect the safety or compliance of patients.
7. Heart function and disease meet one of the following conditions:
1. Heart failure with the classification of New York Heart Association heart function of grade II;
2. A history of unstable angina pectoris;
3. A history of myocardial infarction within the past 1 years;
4. Patients with clinically significant supraventricular or ventricular arrhythmia requiring treatment or intervention;
8. A history of other malignant tumors within the past 5 years (except the cured cervical cancer and basal cell carcinoma of the skin).
9. Patients with active bleeding.
10. Uncontrolled infection exists within 7 days before treatment and parenteral antibiotics, antiviral drugs or antifungal drugs are needed; However, preventive use of these drugs (including parenteral anti-infective drugs) is allowed.
11. Patients with chronic active hepatitis B or active hepatitis C. If the background hepatitis B Surface Antigen (HBsAg) and/or hepatitis B core Antibody (HBcAb) or hepatitis C Virus (HCV) antibody are positive, the further determination for Hepatitis B Virus (HBV) DNA (no more than 2500 copies /mL or 500 IU/mL) and HCV RNA (no more than the lower limit of the assay) can be included. The patients with HBsAg and/or HBcAb positive need to receive anti-HBV drugs.
12. Patients with the infection of human immunodeficiency virus (HIV) and/or acquired Immunodeficiency syndrome.
13. Inability to swallow tablets, presence of malabsorption syndrome, or any other gastrointestinal disease or dysfunction that may affect the absorption of the study drug.
14. Pregnant and lactating women, and subjects of childbearing age who do not want to use contraception.
15. Mentally ill persons or persons unable to obtain informed consent.
16. The investigators think that the patient is not suitable for the study.
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fudan University
OTHER
Antengene Corporation
INDUSTRY
Sun Yat-sen University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Qingqing Cai
chief physician
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sun Yat-sen Universitiy Cancer Center
Guangzhou, Guangdong, China
Fudan University Shanghai Cancer Center
Shanghai, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Qing qing Cai, MD
Role: primary
Rong Tao, MD. PhD.
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B2022-534-01
Identifier Type: -
Identifier Source: org_study_id